MIL OSI Translation. Region: Germany / Deutschland –
Source: BayerFinerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) and the first member of this class of substances to have shown benefits with regard to renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses the overactivation of the mineralocorticoid receptor (MR), which contributes significantly to the progression of the disease / Despite guidelines-based therapies, the risk of the disease progressing to kidney failure and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes / The results of the FIDELIO-DKD study were published simultaneously in the New England Journal of Medicine
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.